<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37703175</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy.</ArticleTitle><Pagination><StartPage>113120</StartPage><MedlinePgn>113120</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2023.113120</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(23)01132-4</ELocationID><Abstract><AbstractText>Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common neuromuscular disorders and has no cure. Due to an unknown molecular mechanism, FSHD displays overlapping manifestations with the neurodegenerative disease amyotrophic lateral sclerosis (ALS). FSHD is caused by aberrant gain of expression of the transcription factor double homeobox 4 (DUX4), which triggers a pro-apoptotic transcriptional program resulting in inhibition of myogenic differentiation and muscle wasting. Regulation of DUX4 activity is poorly known. We identify Matrin 3 (MATR3), whose mutation causes ALS and dominant distal myopathy, as a cellular factor controlling DUX4 expression and activity. MATR3 binds to the DUX4 DNA-binding domain and blocks DUX4-mediated gene expression, rescuing cell viability and myogenic differentiation of FSHD muscle cells, without affecting healthy muscle cells. Finally, we characterize a shorter MATR3 fragment that is necessary and sufficient to directly block DUX4-induced toxicity to the same extent as the full-length protein. Collectively, our data suggest MATR3 as a candidate for developing a treatment for FSHD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Runfola</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Gene Expression and Muscular Dystrophy Unit, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giambruno</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gene Expression and Muscular Dystrophy Unit, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caronni</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gene Expression and Muscular Dystrophy Unit, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pannese</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gene Expression and Muscular Dystrophy Unit, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andolfo</LastName><ForeName>Annapaola</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ProMeFa, Proteomics and Metabolomics Facility, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabellini</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gene Expression and Muscular Dystrophy Unit, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. Electronic address: gabellini.davide@hsr.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 CA249378</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C518587">MATR3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034521">Nuclear Matrix-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005801" MajorTopicYN="N">Genes, Homeobox</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018398" MajorTopicYN="Y">Homeodomain Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020391" MajorTopicYN="Y">Muscular Dystrophy, Facioscapulohumeral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034521" MajorTopicYN="N">Nuclear Matrix-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CP: Developmental biology</Keyword><Keyword MajorTopicYN="N">DUX4</Keyword><Keyword MajorTopicYN="N">FSHD</Keyword><Keyword MajorTopicYN="N">cell toxicity</Keyword><Keyword MajorTopicYN="N">gene regulation</Keyword><Keyword MajorTopicYN="N">muscle differentiation</Keyword></KeywordList><CoiStatement>Declaration of interests D.G., R.G., V.R., and C.C. are inventors of the patent &#x201c;Inhibitor of DUX4 and uses thereof&#x201d; WO/2020/152367. This had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>13</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>13</Day><Hour>12</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37703175</ArticleId><ArticleId IdType="mid">NIHMS1933917</ArticleId><ArticleId IdType="pmc">PMC10591880</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2023.113120</ArticleId><ArticleId IdType="pii">S2211-1247(23)01132-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deenen JCW, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJGM, Bakker E, Weinreich SS, Verbeek ALM, and van Engelen BGM. (2014). Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology 83, 1056&#x2013;1059. 10.1212/WNL.0000000000000797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000797</ArticleId><ArticleId IdType="pmc">PMC4166358</ArticleId><ArticleId IdType="pubmed">25122204</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, and Tawil R. (2014). Risk of functional impairment infacioscapulohumeral muscular dystrophy. Muscle Nerve 49, 520&#x2013;527. 10.1002/mus.23949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23949</ArticleId><ArticleId IdType="pubmed">23873337</ArticleId></ArticleIdList></Reference><Reference><Citation>Padberg GW, Frants RR, Brouwer OF, Wijmenga C, Bakker E, and Sandkuijl LA. (1995). Facioscapulohumeral muscular dystrophy in the dutch population. Muscle Nerve 18, 81&#x2013;84. 10.1002/mus.880181315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880181315</ArticleId><ArticleId IdType="pubmed">23573591</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Odrzywolski KJ, Shah B, Henderson D, Fricke AF, van der Maarel SM, Tapscott SJ, and Tawil R. (2015). Immunohistochemical Characterization of Facioscapulohumeral Muscular Dystrophy Muscle Biopsies. J. Neuromuscul. Dis. 2, 291&#x2013;299. 10.3233/JND-150077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-150077</ArticleId><ArticleId IdType="pmc">PMC4560242</ArticleId><ArticleId IdType="pubmed">26345300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia FF, Drew AP, Nicholson GA, Corbett A, and Kumar KR. (2021). Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings. Neuromuscul. Disord. 31, 1101&#x2013;1112. 10.1016/j.nmd.2021.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2021.09.010</ArticleId><ArticleId IdType="pubmed">34711481</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacconi S, Briand-Suleau A, Gros M, Baudoin C, Lemmers RJLF, Rondeau S, Lagha N, Nigumann P, Cambieri C, Puma A, et al. (2019). FSHD1 and FSHD2 form a disease continuum. Neurology 92, e2273&#x2013;e2285. 10.1212/WNL.0000000000007456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007456</ArticleId><ArticleId IdType="pmc">PMC6537132</ArticleId><ArticleId IdType="pubmed">30979860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmers RJLF, Van Der Vliet PJ, Klooster R, Sacconi S, Cama&#xf1;o P, Dauwerse JG, Snider L, Straasheijm KR, Van Ommen GJ, Padberg GW, et al. (2010). A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329, 1650&#x2013;1653. 10.1126/science.1189044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1189044</ArticleId><ArticleId IdType="pmc">PMC4677822</ArticleId><ArticleId IdType="pubmed">20724583</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocciaro E, Runfola V, Ghezzi P, Pannese M, and Gabellini D. (2021). DUX4 role in normal physiology and in FSHD muscular dystrophy. Cells 10, 3322. 10.3390/cells10123322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123322</ArticleId><ArticleId IdType="pmc">PMC8699294</ArticleId><ArticleId IdType="pubmed">34943834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrickson PG, Dor&#xe1;is JA, Grow EJ, Whiddon JL, Lim J-W, Wike CL, Weaver BD, Pflueger C, Emery BR, Wilcox AL, et al. (2017). Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons. Nat. Genet. 49, 925&#x2013;934. 10.1038/ng.3844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3844</ArticleId><ArticleId IdType="pmc">PMC5703070</ArticleId><ArticleId IdType="pubmed">28459457</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiddon JL, Langford AT, Wong CJ, Zhong JW, and Tapscott SJ. (2017). Conservation and innovation in the DUX4-family gene network. Nat. Genet. 49, 935&#x2013;940. 10.1038/ng.3846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3846</ArticleId><ArticleId IdType="pmc">PMC5446306</ArticleId><ArticleId IdType="pubmed">28459454</ArticleId></ArticleIdList></Reference><Reference><Citation>De Iaco A, Planet E, Coluccio A, Verp S, Duc J, and Trono D. (2017). DUX-family transcription factors regulate zygotic genome activation in placental mammals. Nat. Genet. 49, 941&#x2013;945. 10.1038/ng.3858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3858</ArticleId><ArticleId IdType="pmc">PMC5446900</ArticleId><ArticleId IdType="pubmed">28459456</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace LM, Garwick SE, Mei W, Belayew A, Coppee F, Ladner KJ, Guttridge D, Yang J, and Harper SQ. (2011). DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann. Neurol. 69, 540&#x2013;552. 10.1002/ana.22275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22275</ArticleId><ArticleId IdType="pmc">PMC4098764</ArticleId><ArticleId IdType="pubmed">21446026</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng LN, Yao Z, Snider L, Fong AP, Cech JN, Young JM, vanderMaarel SM, Ruzzo WL, Gentleman RC, Tawil R, and Tapscott SJ. (2012). DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy. Dev. Cell 22, 38&#x2013;51. 10.1016/j.devcel.2011.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2011.11.013</ArticleId><ArticleId IdType="pmc">PMC3264808</ArticleId><ArticleId IdType="pubmed">22209328</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Z, Snider L, Balog J, Lemmers RJLF, van der Maarel SM, Tawil R, and Tapscott SJ. (2014). DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle. Hum. Mol. Genet. 23, 5342&#x2013;5352. 10.1093/hmg/ddu251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu251</ArticleId><ArticleId IdType="pmc">PMC4168822</ArticleId><ArticleId IdType="pubmed">24861551</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickard AM, Petek LM, and Miller DG. (2015). Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways. Hum. Mol. Genet. 24, 5901&#x2013;5914. 10.1093/hmg/ddv315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv315</ArticleId><ArticleId IdType="pmc">PMC4581613</ArticleId><ArticleId IdType="pubmed">26246499</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowaljow V, Marcowycz A, Ansseau E, Conde CB, Sauvage S, Matt&#xe9;otti C, Arias C, Corona ED, Nu&#xf1; ez NG, Leo O, et al. (2007). The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul. Disord. 17, 611&#x2013;623. 10.1016/j.nmd.2007.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2007.04.002</ArticleId><ArticleId IdType="pubmed">17588759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandri M, El Meslemani AH, Sandri C, Schjerling P, Vissing K, Andersen JL, Rossini K, Carraro U, and Angelini C. (2001). Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment? J. Neuropathol. Exp. Neurol. 60, 302&#x2013;312. 10.1093/jnen/60.3.302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/60.3.302</ArticleId><ArticleId IdType="pubmed">11245214</ArticleId></ArticleIdList></Reference><Reference><Citation>Block GJ, Narayanan D, Amell AM, Petek LM, Davidson KC, Bird TD, Tawil R, Moon RT, and Miller DG. (2013). Wnt/&#x3b2;-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells. Hum. Mol. Genet. 22, 4661&#x2013;4672. 10.1093/hmg/ddt314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt314</ArticleId><ArticleId IdType="pmc">PMC3820129</ArticleId><ArticleId IdType="pubmed">23821646</ArticleId></ArticleIdList></Reference><Reference><Citation>Tawil R, McDermott MP, Pandya S, King W, Kissel J, Mendell JR, and Griggs RC. (1997). A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology 48, 46&#x2013;49. 10.1212/wnl.48.1.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.48.1.46</ArticleId><ArticleId IdType="pubmed">9008492</ArticleId></ArticleIdList></Reference><Reference><Citation>Passerieux E, Hayot M, Jaussent A, Carnac G, Gouzi F, Pillard F, Picot M-C, B&#xf6;cker K, Hugon G, Pincemail J, et al. (2015). Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial. Free Radic. Biol. Med. 81, 158&#x2013;169. 10.1016/j.freeradbiomed.2014.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.09.014</ArticleId><ArticleId IdType="pubmed">25246239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissel JT, McDermott MP, Mendell JR, King WM, Pandya S, Griggs RC, and Tawil R; FSH-DY Group (2001). Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57, 1434&#x2013;1440. 10.1212/wnl.57.8.1434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.57.8.1434</ArticleId><ArticleId IdType="pubmed">11673585</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsheikh BH, Bollman E, Peruggia M, King W, Galloway G, and Kissel JT. (2007). Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy. Neurology 68, 1428&#x2013;1429. 10.1212/01.wnl.0000264017.08217.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000264017.08217.39</ArticleId><ArticleId IdType="pubmed">17452589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, Flanigan KM, Pestronk A, Tawil R, Wolfe GI, et al. (2008). A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 63, 561&#x2013;571. 10.1002/ana.21338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21338</ArticleId><ArticleId IdType="pubmed">18335515</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumura T, Yokoe M, Nakamori M, Hattori N, Saito T, Nozaki S, Fujimura H, and Shinno S. (2004). A clinical trial of creatine monohydrate in muscular dystrophy patients. Clin. Neurol. 44, 661&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">15568480</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kooi EL, Kalkman JS, Lindeman E, Hendriks JCM, van Engelen BGM, Bleijenberg G, and Padberg GW. (2007). Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. J. Neurol. 254, 931&#x2013;940. 10.1007/s00415-006-0432-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0432-4</ArticleId><ArticleId IdType="pmc">PMC2779375</ArticleId><ArticleId IdType="pubmed">17361345</ArticleId></ArticleIdList></Reference><Reference><Citation>Payan CA, Hogrel JY, Hammouda EH, Lacomblez L, Ollivier G, Doppler V, Eymard B, Attarian S, Pouget J, Desnuelle C, and Lafor&#xea;t P. (2009). Periodic Salbutamol in Facioscapulohumeral Muscular Dystrophy: A Randomized Controlled Trial. Arch. Phys. Med. Rehabil. 90, 1094&#x2013;1101. 10.1016/j.apmr.2008.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apmr.2008.12.027</ArticleId><ArticleId IdType="pubmed">19577021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellion ML, Ronco L, Berends CL, Pagan L, Brooks S, van Esdonk MJ, van Brummelen EMJ, Odueyungbo A, Thompson LA, Hage M, et al. (2021). Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. Br. J. Clin. Pharmacol. 87, 4658&#x2013;4669. 10.1111/bcp.14884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14884</ArticleId><ArticleId IdType="pubmed">33931884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitzia C, Meregalli M, Belicchi M, Farini A, Arosio M, Bestetti D, Villa C, Valenti L, Brambilla P, and Torrente Y. (2019). Preliminary evidences of safety and efficacy of flavonoids- And omega 3-based compound for muscular dystrophies treatment: A randomized double-blind placebo controlled pilot clinical trial. Front. Neurol. 10, 755. 10.3389/fneur.2019.00755.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00755</ArticleId><ArticleId IdType="pmc">PMC6664031</ArticleId><ArticleId IdType="pubmed">31396142</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser CE, Gartner MR, Wilson D, Miller B, Sherman ML, and Attie KM. (2018). Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve 57, 921&#x2013;926. 10.1002/mus.26113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26113</ArticleId><ArticleId IdType="pmc">PMC5969095</ArticleId><ArticleId IdType="pubmed">29486514</ArticleId></ArticleIdList></Reference><Reference><Citation>Homma S, Beermann ML, Boyce FM, and Miller JB. (2015). Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation. Ann. Clin. Transl. Neurol. 2, 151&#x2013;166. 10.1002/acn3.158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.158</ArticleId><ArticleId IdType="pmc">PMC4338956</ArticleId><ArticleId IdType="pubmed">25750920</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerji CRS, and Zammit PS. (2021). Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7. EMBO Mol. Med. 13, e13695. 10.15252/emmm.202013695.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202013695</ArticleId><ArticleId IdType="pmc">PMC8350899</ArticleId><ArticleId IdType="pubmed">34151531</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim KRQ, Nguyen Q, and Yokota T. (2020). Dux4 signalling in the pathogenesis of facioscapulohumeral muscular dystrophy. Int. J. Mol. Sci. 21, 729. 10.3390/ijms21030729.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21030729</ArticleId><ArticleId IdType="pmc">PMC7037115</ArticleId><ArticleId IdType="pubmed">31979100</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;tzl T, Kaiser L, and Deigner HP. (2021). Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update. Orphanet J. Rare Dis. 16, 129. 10.1186/s13023-021-01760-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-021-01760-1</ArticleId><ArticleId IdType="pmc">PMC7953708</ArticleId><ArticleId IdType="pubmed">33712050</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagannathan S, Shadle SC, Resnick R, Snider L, Tawil RN, van der Maarel SM, Bradley RK, and Tapscott SJ. (2016). Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells. Hum. Mol. Genet. 25, 4419&#x2013;4431. 10.1093/hmg/ddw271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw271</ArticleId><ArticleId IdType="pmc">PMC6078597</ArticleId><ArticleId IdType="pubmed">28171552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosnakovski D, Xu Z, Gang EJ, Galindo CL, Liu M, Simsek T, Garner HR, Agha-Mohammadi S, Tassin A, Copp&#xe9;e F, et al. (2008). An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J. 27, 2766&#x2013;2779. 10.1038/emboj.2008.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2008.201</ArticleId><ArticleId IdType="pmc">PMC2572182</ArticleId><ArticleId IdType="pubmed">18833193</ArticleId></ArticleIdList></Reference><Reference><Citation>Dmitriev P, Bou Saada Y, Dib C, Ansseau E, Barat A, Hamade A, Dessen P, Robert T, Lazar V, Louzada RAN, et al. (2016). DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients. Free Radic. Biol. Med. 99, 244&#x2013;258. 10.1016/j.freeradbiomed.2016.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2016.08.007</ArticleId><ArticleId IdType="pubmed">27519269</ArticleId></ArticleIdList></Reference><Reference><Citation>Barro M, Carnac G, Flavier S, Mercier J, Vassetzky Y, and Laoudj-Chenivesse D. (2010). Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects. J. Cell Mol. Med. 14, 275&#x2013;289. 10.1111/j.1582-4934.2008.00368.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00368.x</ArticleId><ArticleId IdType="pmc">PMC2910739</ArticleId><ArticleId IdType="pubmed">18505476</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderplanck C, Ansseau E, Charron S, Stricwant N, Tassin A, Laoudj-Chenivesse D, Wilton SD, Copp&#xe9;e F, and Belayew A. (2011). The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One 6, e26820. 10.1371/journal.pone.0026820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026820</ArticleId><ArticleId IdType="pmc">PMC3203905</ArticleId><ArticleId IdType="pubmed">22053214</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadle SC, Zhong JW, Campbell AE, Conerly ML, Jagannathan S, Wong CJ, Morello TD, van der Maarel SM, and Tapscott SJ. (2017). DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy. PLoS Genet. 13, e1006658. 10.1371/journal.pgen.1006658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006658</ArticleId><ArticleId IdType="pmc">PMC5362247</ArticleId><ArticleId IdType="pubmed">28273136</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Wang Z, Jin S, Hao H, Zheng L, Zhou B, Zhang W, Lv H, and Yuan Y. (2014). Dux4 induces cell cycle arrest at G1 phase through upregulation of p21 expression. Biochem. Biophys. Res. Commun. 446, 235&#x2013;240. 10.1016/j.bbrc.2014.02.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2014.02.105</ArticleId><ArticleId IdType="pubmed">24589735</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Snider L, Jagannathan S, Tawil R, van der Maarel SM, Tapscott SJ, and Bradley RK. (2015). A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy. Elife 4, e04996. 10.7554/eLife.04996.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.04996</ArticleId><ArticleId IdType="pmc">PMC4383350</ArticleId><ArticleId IdType="pubmed">25564732</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadle SC, Bennett SR, Wong CJ, Karreman NA, Campbell AE, van der Maarel SM, Bass BL, and Tapscott SJ. (2019). DUX4-induced bidirectional HSATII satellite repeat transcripts form intranuclear double-stranded RNA foci in human cell models of FSHD. Hum. Mol. Genet. 28, 3997&#x2013;4011. 10.1093/hmg/ddz242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz242</ArticleId><ArticleId IdType="pmc">PMC7342170</ArticleId><ArticleId IdType="pubmed">31630170</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik AM, and Barmada SJ. (2021). Matrin 3 in neuromuscular disease: physiology and pathophysiology. JCI Insight 6, e143948. 10.1172/jci.insight.143948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.143948</ArticleId><ArticleId IdType="pmc">PMC7821588</ArticleId><ArticleId IdType="pubmed">33427209</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Gearhart MD, Cui Z, Bosnakovski D, Kim M, Schennum N, and Kyba M. (2016). DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes. Nucleic Acids Res. 44, 5161&#x2013;5173. 10.1093/nar/gkw141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw141</ArticleId><ArticleId IdType="pmc">PMC4914088</ArticleId><ArticleId IdType="pubmed">26951377</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, and S&#xe9;raphin B. (1999). A generic protein purification method for protein complex characterization and proteome exploration. Nat. Biotechnol. 17, 1030&#x2013;1032. 10.1038/13732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/13732</ArticleId><ArticleId IdType="pubmed">10504710</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;cher T, and Superti-Furga G. (2007). Mass spectrometry&#x2013;based functional proteomics: from molecular machines to protein networks. Nat. Methods 4, 807&#x2013;815. 10.1038/nmeth1093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth1093</ArticleId><ArticleId IdType="pubmed">17901870</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatter T, Wepf A, Aebersold R, and Gstaiger M. (2009). An integrated workflow for charting the human interaction proteome: insights into the PP2A system. Mol. Syst. Biol. 5, 237. 10.1038/msb.2008.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/msb.2008.75</ArticleId><ArticleId IdType="pmc">PMC2644174</ArticleId><ArticleId IdType="pubmed">19156129</ArticleId></ArticleIdList></Reference><Reference><Citation>Varjosalo M, Sacco R, Stukalov A, van Drogen A, Planyavsky M, Hauri S, Aebersold R, Bennett KL, Colinge J, Gstaiger M, and Superti-Furga G. (2013). Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nat. Methods 10, 307&#x2013;314. 10.1038/nmeth.2400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2400</ArticleId><ArticleId IdType="pubmed">23455922</ArticleId></ArticleIdList></Reference><Reference><Citation>Belgrader P, Dey R, and Berezney R. (1991). Molecular cloning of matrin 3. A 125-kilodalton protein of the nuclear matrix contains an extensive acidic domain. J. Biol. Chem. 266, 9893&#x2013;9899.</Citation><ArticleIdList><ArticleId IdType="pubmed">2033075</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem A, Wilson CJ, Rutledge BS, Dilliott A, Farhan S, Choy WY, and Duennwald ML. (2021). Matrin3: Disorder and ALS Pathogenesis. Front. Mol. Biosci. 8, 794646. 10.3389/fmolb.2021.794646.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.794646</ArticleId><ArticleId IdType="pmc">PMC8784776</ArticleId><ArticleId IdType="pubmed">35083279</ArticleId></ArticleIdList></Reference><Reference><Citation>Tassin A, Laoudj-Chenivesse D, Vanderplanck C, Barro M, Charron S, Ansseau E, Chen YW, Mercier J, Copp&#xe9;e F, and Belayew A. (2013). DUX4 expression in FSHD muscle cells: How could such a rare protein cause a myopathy? J. Cell Mol. Med. 17, 76&#x2013;89. 10.1111/j.1582-4934.2012.01647.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2012.01647.x</ArticleId><ArticleId IdType="pmc">PMC3823138</ArticleId><ArticleId IdType="pubmed">23206257</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider L, Geng LN, Lemmers RJLF, Kyba M, Ware CB, Nelson AM, Tawil R, Filippova GN, van der Maarel SM, Tapscott SJ, and Miller DG. (2010). Facioscapulohumeral dystrophy: Incomplete suppression of a retrotransposed gene. PLoS Genet. 6, e1001181. 10.1371/journal.pgen.1001181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1001181</ArticleId><ArticleId IdType="pmc">PMC2965761</ArticleId><ArticleId IdType="pubmed">21060811</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;derberg O, Leuchowius K-J, Gullberg M, Jarvius M, Weibrecht I, Larsson L-G, and Landegren U. (2008). Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 45, 227&#x2013;232. 10.1016/j.ymeth.2008.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2008.06.014</ArticleId><ArticleId IdType="pubmed">18620061</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocciaro E, Giambruno R, Micheloni S, Cernilogar FM, Andolfo A, Consonni C, Pannese M, Ferri G, Runfola V, Schotta G, and Gabellini D. (2023). WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy. Nucleic Acids Res. 51, 5144&#x2013;5161. 10.1093/nar/gkad230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkad230</ArticleId><ArticleId IdType="pmc">PMC10250208</ArticleId><ArticleId IdType="pubmed">37021550</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona ED, Jacquelin D, Gatica L, and Rosa AL. (2013). Multiple Protein Domains Contribute to Nuclear Import and Cell Toxicity of DUX4, a Candidate Pathogenic Protein for Facioscapulohumeral Muscular Dystrophy. PLoS One 8, e75614. 10.1371/journal.pone.0075614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075614</ArticleId><ArticleId IdType="pmc">PMC3792938</ArticleId><ArticleId IdType="pubmed">24116060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones TI, Chen JCJ, Rahimov F, Homma S, Arashiro P, Beermann ML, King OD, Miller JB, Kunkel LM, Emerson CP, et al. (2012). Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum. Mol. Genet. 21, 4419&#x2013;4430. 10.1093/hmg/dds284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds284</ArticleId><ArticleId IdType="pmc">PMC3459465</ArticleId><ArticleId IdType="pubmed">22798623</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron L, Kher D, Lee KL, McKernan R, Dumevska B, Hidalgo A, Li J, Yang H, Main H, Ferri G, et al. (2016). A human pluripotent stem cell model of facioscapulohumeral muscular dystrophy-affected skeletal muscles. Stem Cells Transl. Med. 5, 1145&#x2013;1161. 10.5966/sctm.2015-0224.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2015-0224</ArticleId><ArticleId IdType="pmc">PMC4996435</ArticleId><ArticleId IdType="pubmed">27217344</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J, DeSimone A, Lek M, and Lek A. (2021). Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy. Trends Mol. Med. 27, 123&#x2013;137. 10.1016/j.molmed.2020.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2020.09.008</ArticleId><ArticleId IdType="pmc">PMC8048701</ArticleId><ArticleId IdType="pubmed">33092966</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell AE, Shadle SC, Jagannathan S, Lim J-W, Resnick R, Tawil R, van der Maarel SM, and Tapscott SJ. (2018). NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins. Elife 7, e31023. 10.7554/eLife.31023.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.31023</ArticleId><ArticleId IdType="pmc">PMC5849414</ArticleId><ArticleId IdType="pubmed">29533181</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik AM, Miguez RA, Li X, Ho Y-S, Feldman EL, and Barmada SJ. (2018). Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization. Elife 7, e35977. 10.7554/eLife.35977.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.35977</ArticleId><ArticleId IdType="pmc">PMC6050042</ArticleId><ArticleId IdType="pubmed">30015619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh N, Kour S, Anderson EN, Rajasundaram D, and Pandey UB. (2020). RNA-recognition motif in Matrin-3 mediates neurodegeneration through interaction with hnRNPM. Acta Neuropathol. Commun. 8, 138. 10.1186/s40478-020-01021-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01021-5</ArticleId><ArticleId IdType="pmc">PMC7437177</ArticleId><ArticleId IdType="pubmed">32811564</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprunger ML, Lee K, Sohn BS, and Jackrel ME. (2022). Molecular determinants and modifiers of Matrin-3 toxicity, condensate dynamics, and droplet morphology. iScience 25, 103900. 10.1016/j.isci.2022.103900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.103900</ArticleId><ArticleId IdType="pmc">PMC8889142</ArticleId><ArticleId IdType="pubmed">35252808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, and Neumann M. (2010). TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9, 995&#x2013;1007. 10.1016/S1474-4422(10)70195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Douville R, Liu J, Rothstein J, and Nath A. (2011). Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann. Neurol. 69, 141&#x2013;151. 10.1002/ana.22149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22149</ArticleId><ArticleId IdType="pmc">PMC3052883</ArticleId><ArticleId IdType="pubmed">21280084</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee M-H, Henderson L, Tyagi R, Bachani M, Steiner J, Campanac E, Hoffman DA, von Geldern G, Johnson K, et al. (2015). Human endogenous retrovirus-K contributes to motor neuron disease. Sci. Transl. Med. 7, 307ra153. 10.1126/scitranslmed.aac8201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac8201</ArticleId><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen LN, Tyagi R, Li W, Alfahad T, Smith B, Wright M, Singer EJ, and Nath A. (2016). HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. Neurology 87, 1756&#x2013;1762. 10.1212/WNL.0000000000003258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003258</ArticleId><ArticleId IdType="pmc">PMC5089528</ArticleId><ArticleId IdType="pubmed">27664983</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug L, Chatterjee N, Borges-Monroy R, Hearn S, Liao W-W, Morrill K, Prazak L, Rozhkov N, Theodorou D, Hammell M, and Dubnau J. (2017). Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. PLoS Genet. 13, e1006635. 10.1371/journal.pgen.1006635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006635</ArticleId><ArticleId IdType="pmc">PMC5354250</ArticleId><ArticleId IdType="pubmed">28301478</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, and Cleveland DW. (2016). Decoding ALS: from genes to mechanism. Nature 539, 197&#x2013;206. 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JM, Whiddon JL, Yao Z, Kasinathan B, Snider L, Geng LN, Balog J, Tawil R, van der Maarel SM, and Tapscott SJ. (2013). DUX4 Binding to Retroelements Creates Promoters That Are Active in FSHD Muscle and Testis. PLoS Genet. 9, e1003947. 10.1371/journal.pgen.1003947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1003947</ArticleId><ArticleId IdType="pmc">PMC3836709</ArticleId><ArticleId IdType="pubmed">24278031</ArticleId></ArticleIdList></Reference><Reference><Citation>Winokur ST, Barrett K, Martin JH, Forrester JR, Simon M, Tawil R, Chung S-A, Masny PS, and Figlewicz DA. (2003). Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul. Disord. 13, 322&#x2013;333. 10.1016/s0960-8966(02)00284-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0960-8966(02)00284-5</ArticleId><ArticleId IdType="pubmed">12868502</ArticleId></ArticleIdList></Reference><Reference><Citation>Turki A, Hayot M, Carnac G, Pillard F, Passerieux E, Bommart S, Raynaud de Mauverger E, Hugon G, Pincemail J, Pietri S, et al. (2012). Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction. Free Radic. Biol. Med. 53, 1068&#x2013;1079. 10.1016/j.free-radbiomed.2012.06.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.free-radbiomed.2012.06.041</ArticleId><ArticleId IdType="pubmed">22796148</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandapat A, Bosnakovski D, Hartweck LM, Arpke RW, Baltgalvis KA, Vang D, Baik J, Darabi R, Perlingeiro RCR, Hamra FK, et al. (2014). Dominant Lethal Pathologies in Male Mice Engineered to Contain an X-Linked DUX4 Transgene. Cell Rep. 8, 1484&#x2013;1496. 10.1016/j.celrep.2014.07.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.07.056</ArticleId><ArticleId IdType="pmc">PMC4188423</ArticleId><ArticleId IdType="pubmed">25176645</ArticleId></ArticleIdList></Reference><Reference><Citation>Senderek J, Garvey SM, Krieger M, Guergueltcheva V, Urtizberea A, Roos A, Elbracht M, Stendel C, Tournev I, Mihailova V, et al. (2009). Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am. J. Hum. Genet. 84, 511&#x2013;518. 10.1016/j.ajhg.2009.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2009.03.006</ArticleId><ArticleId IdType="pmc">PMC2667977</ArticleId><ArticleId IdType="pubmed">19344878</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehringer A, Garcia-Mansfield K, Singh G, Bakkar N, Pirrotte P, and Bowser R. (2017). ALS Associated Mutations in Matrin 3 Alter Protein-Protein Interactions and Impede mRNA Nuclear Export. Sci. Rep. 7, 14529. 10.1038/s41598-017-14924-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14924-6</ArticleId><ArticleId IdType="pmc">PMC5674072</ArticleId><ArticleId IdType="pubmed">29109432</ArticleId></ArticleIdList></Reference><Reference><Citation>Neguembor MV, Previtali S, and Gabellini D. (2015). Facioscapulohumeral Dystrophy. In TheOnline Metabolic and Molecular Bases of Inherited Disease, Valle DL, Antonarakis SE, Ballabio A, Beaudet AL, and Mitchell GA, eds. (McGraw-Hill Medical; ). 10.1036/ommbid.216.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1036/ommbid.216.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LH, and Tawil R. (2016). Facioscapulohumeral Dystrophy. Curr. Neurol. Neurosci. Rep. 16, 66. 10.1007/s11910-016-0667-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-016-0667-0</ArticleId><ArticleId IdType="pubmed">27215221</ArticleId></ArticleIdList></Reference><Reference><Citation>Mul K, Voermans NC, Lemmers RJLF, Jonker MA, van der Vliet PJ, Padberg GW, van Engelen BGM, van der Maarel SM, and Horlings CGC. (2018). Phenotype-genotype relations in facioscapulohumeral muscular dystrophy type 1. Clin. Genet. 94, 521&#x2013;527. 10.1111/cge.13446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.13446</ArticleId><ArticleId IdType="pubmed">30211448</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton M, Elkon R, Borodina T, Davydov A, Yaspo ML, Halperin E, and Shiloh Y. (2011). Matrin 3 binds and stabilizes mRNA. PLoS One 6, e23882. 10.1371/JOURNAL.PONE.0023882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0023882</ArticleId><ArticleId IdType="pmc">PMC3157474</ArticleId><ArticleId IdType="pubmed">21858232</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Q, He W, Zhang XHF, Le HV, and Massagu&#xe9; J. (2008). Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program. J. Biol. Chem. 283, 1146&#x2013; 1155. 10.1074/JBC.M707479200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/JBC.M707479200</ArticleId><ArticleId IdType="pmc">PMC2692279</ArticleId><ArticleId IdType="pubmed">18003620</ArticleId></ArticleIdList></Reference><Reference><Citation>Banko MR, Allen JJ, Schaffer BE, Wilker EW, Tsou P, White JL, Vill&#xe9;n J, Wang B, Kim SR, Sakamoto K, et al. (2011). Chemical genetic screen for AMPK&#x3b1;2 substrates uncovers a network of proteins involved in mitosis. Mol. Cell 44, 878&#x2013;892. 10.1016/J.MOL-CEL.2011.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MOL-CEL.2011.11.005</ArticleId><ArticleId IdType="pmc">PMC3246132</ArticleId><ArticleId IdType="pubmed">22137581</ArticleId></ArticleIdList></Reference><Reference><Citation>Venteicher AS, Meng Z, Mason PJ, Veenstra TD, and Artandi SE. (2008). Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 132, 945&#x2013;957. 10.1016/J.CELL.2008.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2008.01.019</ArticleId><ArticleId IdType="pmc">PMC2291539</ArticleId><ArticleId IdType="pubmed">18358808</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, and Mann M. (2011). Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794&#x2013;1805. 10.1021/pr101065j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr101065j</ArticleId><ArticleId IdType="pubmed">21254760</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21. 10.1093/BIOINFORMATICS/BTS635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/BIOINFORMATICS/BTS635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, and Shi W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923&#x2013;930. 10.1093/BIOINFORMATICS/BTT656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/BIOINFORMATICS/BTT656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, and Wagner G. (2010). Overcoming the solubility limit with solubility-enhancement tags: successful applications in biomolecular NMR studies. J. Biomol. NMR 46, 23&#x2013;31. 10.1007/s10858-009-9371-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10858-009-9371-6</ArticleId><ArticleId IdType="pmc">PMC2879018</ArticleId><ArticleId IdType="pubmed">19731047</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambruno R, Grebien F, Stukalov A, Knoll C, Planyavsky M, Rudashevskaya EL, Colinge J, Superti-Furga G, and Bennett KL. (2013). Affinity purification strategies for proteomic analysis of transcription factor complexes. J. Proteome Res. 12, 4018&#x2013;4027. 10.1021/pr4003323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr4003323</ArticleId><ArticleId IdType="pmc">PMC3768224</ArticleId><ArticleId IdType="pubmed">23937658</ArticleId></ArticleIdList></Reference><Reference><Citation>Wi&#x15b;niewski JR, Zougman A, Nagaraj N, and Mann M. (2009). Universal sample preparation method for proteome analysis. Nat. Methods 6, 359&#x2013;362. 10.1038/nmeth.1322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1322</ArticleId><ArticleId IdType="pubmed">19377485</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber ML, Sacco R, Parapatics K, Skucha A, Khamina K, M&#xfc;ller AC, Rudashevskaya EL, and Bennett KL. (2014). abFASP-MS: affinity-based filter-aided sample preparation mass spectrometry for quantitative analysis of chemically labeled protein complexes. J. Proteome Res. 13, 1147&#x2013;1155. 10.1021/pr4009892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr4009892</ArticleId><ArticleId IdType="pmc">PMC3923452</ArticleId><ArticleId IdType="pubmed">24400740</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, and Anders S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, and Hochberg Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. Roy. Stat. Soc. B 57, 289&#x2013;300. 10.1111/j.2517-6161.1995.tb02031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>